AI Article Synopsis
- The study examines the effectiveness of autologous stem cell transplantation (ASCT) in preventing central nervous system (CNS) plasmacytomas in multiple myeloma (MM) patients, highlighting a specific case where ASCT failed to prevent lesions.
- A 42-year-old female with a history of MM underwent ASCT and later experienced severe headaches and vision loss, leading to the discovery of multiple intracranial tumors that were confirmed as plasmacytomas.
- The findings suggest that ASCT generally does not prevent CNS plasmacytomas in most MM patients, particularly those with the immunoglobulin A (IgA) subtype, which is more aggressive.
Article Abstract
Background: The effectiveness of autologous stem cell transplantation (ASCT) in preventing the development of central nervous system (CNS) plasmacytomas in multiple myeloma (MM) patients is not well understood. An ASCT patient who developed CNS extramedullary (EM) lesions is presented. The literature was reviewed for similar cases in which the transplant did not prevent the development of CNS lesions.
Case Description: A 42-year-old female was evaluated after complaining of a sudden severe headache and complete vision loss. Two years before, she was diagnosed with MM and treated with systemic chemotherapy and an ASCT. The patient was in remission; however, a new brain magnetic resonance imaging showed a sellar and suprasellar mass. Additional smaller lesions were identified at the parietal convexity and the splenium. Due to the history of MM and evidence of multiple intracranial lesions, it was suspected that the lesions were secondary to EM disseminated disease. Due to the sudden loss of vision, the patient underwent a right frontotemporal craniotomy with subtotal sellar/suprasellar tumor resection to decompress the optic nerves. Histopathological examination of the lesion confirmed an immunoglobulin A (IgA) EM sellar and suprasellar plasmacytoma.
Conclusion: In the majority of MM patients with CNS involvement, ASCT did not prevent the development of EM sellar plasmacytomas. The IgA subtype is associated with more aggressive disease biology for CNS relapses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10858770 | PMC |
| http://dx.doi.org/10.25259/SNI_964_2023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytology to More Clearly Distinguish Solitary Plasmacytoma at the Skull Base.
Diagn Cytopathol
January 2025
Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Solitary plasmacytomas are localized single tumors of monoclonal plasma cells that occur in two variants: solitary plasmacytoma of bone and extraosseous plasmacytoma. Solitary plasmacytoma of bone accounts for only 1%-2% of plasma cell lesions, and extraosseous plasmacytoma is also approximately 1%. These are both very uncommon at the skull base.
View Article and Find Full Text PDFRathke cleft cyst with squamous metaplasia and activating mutations of mitogen-activated protein kinase signaling: illustrative case.
J Neurosurg Case Lessons
January 2025
Department of Neurological Surgery, University of California, San Diego, La Jolla, California.
Background: Rathke cleft cysts (RCCs) are benign sellar/suprasellar lesions that result from mucin-secreting vestigial remnants within the pars intermedia of the pituitary gland. When symptomatic, they can present with retro-orbital headaches, visual field defects, and/or pituitary dysfunction.
Observations: A 35-year-old female presented with subacute retro-orbital headache, right ptosis, and blurred vision.
Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy.
Sci Rep
January 2025
Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Carl Von Ossietzky Universität, Klinikum Oldenburg AöR, Rahel-Straus-Straße 10, 26133, Oldenburg, Germany.
Survivors of sellar/suprasellar tumors involving hypothalamic structures face a risk of impaired quality of life, including tumor- and/or treatment-related hypothalamic obesity (TTR-HO) defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment related damage of the hypothalamus. We analyze German claims data to better understand treatment pathways for patients living TTR-HO during the two years following the index surgical treatment. A database algorithm identified patients with TTR-HO in a representative German payer claims database between 2010 and 2021 (n = 5.
View Article and Find Full Text PDFUse of a Novel Steerable Tip Suction Cannula in Large and Giant Pituitary Adenomas: A Cadaveric Feasibility Study.
Surg Innov
January 2025
Department of Neurosurgery, Istanbul University, Faculty of Medicine, Istanbul, Turkey.
Objective: The endoscopic transsphenoidal approach is commonly used for sellar and suprasellar pathologies. However, reaching above the diaphragma sella, especially for posterosuperior and retrocavernous orientation, still poses some challenges. We designed and developed a steerable tip suction cannula (STSC) that has distinct leverage for endoscopic resection of such pathologies.
View Article and Find Full Text PDFIntrasellar Tuberculosis Presenting as Pituitary Apoplexy: A Case Report.
Cureus
December 2024
Department of Neurosurgery, NMC Royal Hospital, Abu Dhabi, ARE.
Patients presenting with acute onset of headache and ophthalmoplegia are clinically diagnosed as having a pituitary adenoma with apoplexy. Rarely, other diseases can mimic this condition clinically and radiologically, requiring a high index of suspicion to reach the correct diagnosis. We present a case of a 37-year-old male of Indian origin, who had intra- and supra-sellar tuberculosis (TB), presenting with classical clinical features of pituitary apoplexy and constitutional symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!